133 related articles for article (PubMed ID: 16400521)
1. Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice.
Axelsson H; Lönnroth C; Wang W; Svanberg E; Lundholm K
Angiogenesis; 2005; 8(4):339-48. PubMed ID: 16400521
[TBL] [Abstract][Full Text] [Related]
2. The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors.
Cahlin C; Gelin J; Andersson M; Lönnroth C; Lundholm K
Int J Oncol; 2005 Oct; 27(4):913-23. PubMed ID: 16142306
[TBL] [Abstract][Full Text] [Related]
3. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids.
Cahlin C; Gelin J; Delbro D; Lönnroth C; Doi C; Lundholm K
Cancer Res; 2000 Mar; 60(6):1742-9. PubMed ID: 10749148
[TBL] [Abstract][Full Text] [Related]
4. Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE2 production and prostaglandin related cachexia.
Wang W; Andersson M; Lönnroth C; Svanberg E; Lundholm K
J Exp Clin Cancer Res; 2005 Mar; 24(1):99-107. PubMed ID: 15943039
[TBL] [Abstract][Full Text] [Related]
5. Indomethacin and telomerase activity in tumor growth retardation.
Lönnroth C; Andersson M; Lundholm K
Int J Oncol; 2001 May; 18(5):929-37. PubMed ID: 11295037
[TBL] [Abstract][Full Text] [Related]
6. Lipopolysaccharide stimulates the production of prostaglandin E2 and the receptor Ep4 in osteoblasts.
Shoji M; Tanabe N; Mitsui N; Tanaka H; Suzuki N; Takeichi O; Sugaya A; Maeno M
Life Sci; 2006 Mar; 78(17):2012-8. PubMed ID: 16289620
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors.
Hatazawa R; Tanaka A; Tanigami M; Amagase K; Kato S; Ashida Y; Takeuchi K
Am J Physiol Gastrointest Liver Physiol; 2007 Oct; 293(4):G788-97. PubMed ID: 17673547
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice.
Santander S; Cebrián C; Esquivias P; Conde B; Esteva F; Jiménez P; Ortego J; Lanas A; Piazuelo E
Int J Oncol; 2012 Feb; 40(2):527-34. PubMed ID: 21971589
[TBL] [Abstract][Full Text] [Related]
9. Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis.
Kubo H; Hosono K; Suzuki T; Ogawa Y; Kato H; Kamata H; Ito Y; Amano H; Kato T; Sakagami H; Hayashi I; Sugimoto Y; Narumiya S; Watanabe M; Majima M
Biomed Pharmacother; 2010 Feb; 64(2):101-6. PubMed ID: 20034758
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.
Seno H; Oshima M; Ishikawa TO; Oshima H; Takaku K; Chiba T; Narumiya S; Taketo MM
Cancer Res; 2002 Jan; 62(2):506-11. PubMed ID: 11809702
[TBL] [Abstract][Full Text] [Related]
11. Involvement of cyclooxygenase-1, prostaglandin E2 and EP1 receptors in acid-induced HCO3- secretion in stomach.
Takeuchi K; Aihara E; Sasaki Y; Nomura Y; Ise F
J Physiol Pharmacol; 2006 Dec; 57(4):661-76. PubMed ID: 17229989
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2-derived prostaglandin E2 is involved in vascular endothelial growth factor production in interleukin-1alpha-stimulated human periodontal ligament cells.
Bando Y; Noguchi K; Kobayashi H; Yoshida N; Ishikawa I; Izumi Y
J Periodontal Res; 2009 Jun; 44(3):395-401. PubMed ID: 19210337
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
Hansen-Petrik MB; McEntee MF; Jull B; Shi H; Zemel MB; Whelan J
Cancer Res; 2002 Jan; 62(2):403-8. PubMed ID: 11809688
[TBL] [Abstract][Full Text] [Related]
14. Recruited bone marrow cells expressing the EP3 prostaglandin E receptor subtype enhance angiogenesis during chronic inflammation.
Ueno T; Suzuki T; Oikawa A; Hosono K; Kosaka Y; Amano H; Kitasato H; Toda M; Hayashi I; Kato T; Ito Y; Sugimoto Y; Narumiya S; Okamoto H; Majima M
Biomed Pharmacother; 2010 Feb; 64(2):93-100. PubMed ID: 20015609
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E prevents indomethacin-induced gastric and intestinal damage through different EP receptor subtypes.
Kunikata T; Araki H; Takeeda M; Kato S; Takeuchi K
J Physiol Paris; 2001; 95(1-6):157-63. PubMed ID: 11595431
[TBL] [Abstract][Full Text] [Related]
16. Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus.
Piazuelo E; Jiménez P; Strunk M; Santander S; García A; Esteva F; Lanas A
Prostaglandins Other Lipid Mediat; 2006 Dec; 81(3-4):150-61. PubMed ID: 17085323
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis.
Rozic JG; Chakraborty C; Lala PK
Int J Cancer; 2001 Aug; 93(4):497-506. PubMed ID: 11477553
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow-derived EP3-expressing stromal cells enhance tumor-associated angiogenesis and tumor growth.
Ogawa Y; Suzuki T; Oikawa A; Hosono K; Kubo H; Amano H; Ito Y; Kitasato H; Hayashi I; Kato T; Sugimoto Y; Narumiya S; Watanabe M; Majima M
Biochem Biophys Res Commun; 2009 May; 382(4):720-5. PubMed ID: 19318087
[TBL] [Abstract][Full Text] [Related]
19. Roles of cyclooxygenase-2 and prostacyclin/IP receptors in mucosal defense against ischemia/reperfusion injury in mouse stomach.
Kotani T; Kobata A; Nakamura E; Amagase K; Takeuchi K
J Pharmacol Exp Ther; 2006 Feb; 316(2):547-55. PubMed ID: 16236816
[TBL] [Abstract][Full Text] [Related]
20. Involvement of prostaglandin E receptor EP3 subtype and prostacyclin IP receptor in decreased acid response in damaged stomach.
Nishio H; Terashima S; Nakashima M; Aihara E; Takeuchi K
J Physiol Pharmacol; 2007 Sep; 58(3):407-21. PubMed ID: 17928639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
